Notification and public disclosure of transactions by persons discharging managerial responsibilities
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Douglas Hurt |
| 2 | Reason for the notification | |
| a) | Position/status | Non-Executive Director |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Hikma Pharmaceuticals PLC |
| b) | LEI | 549300BNS685UXH4JI75 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
| b) | Nature of the transaction
| Market purchase of 1,500 Ordinary Shares by Gillian Hurt, spouse of Douglas Hurt |
| c) | Price(s) and volume(s) | Price(s): £22.65 Volume(s): 1,500 |
| d) | Aggregated information - Volume - Price - Total |
1,500 £22.65 £33,975 |
| e) | Date of the transaction | 2 March 2021 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Peter Speirs
Company Secretary, responsible for releasing this announcement
+44 (0) 20 7399 2760
2 March 2021
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
